In rural America, where rheumatology offices are fewer and farther between, the expansion of telemedicine has been a boon during the COVID-19 pandemic. However, lab closures and reduced hospital services have made monitoring patients’ medications more challenging.
Three experts discuss recent developments in the diagnosis & treatment of APS & the future direction of research.
The Global Rheumatology Alliance is an important tool for assessing COVID-19 risk, & the ACR COVID-19 Task Force provides treatment guidance to rheumatology practitioners.
Immune checkpoint inhibitors effectively treat malignancy in ways that were not possible just a few years ago, but immune-related adverse events are a potential side effect.
While an active member of her state rheumatology society, L. Manuela Marinescu, MD, saw the value of connecting with other regional groups to share information and advocacy strategies. On Nov. 16, she assumed the role of chair of the ACR’s Affiliate Society Council (ASC), where she will help facilitate those connections. Dr. Marinescu graduated with…
The use of warfarin may increase the risk of knee or hip replacement in patients with osteoarthritis (OA), according to research presented during ACR Convergence 2020.
The FDA issued an emergency use authorization for the use of baricitinib combined with remdesivir to treat patients hospitalized with COVID-19.
Some aspects of community practice are normalizing amid the ongoing COVID-19 pandemic, but the financial fallout and the need for increased safety precautions remain challenging.
Three experts discuss the current evidence on potential pathogenic mechanisms underlying preclinical RA autoimmunity and subsequent active disease.
With his clinic resuming in-person visits, Jay Mehta, MD, says his patients and staff have proved remarkably adaptable, embracing telemedicine during the early days of the pandemic and now facemasks during appointments.